These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 2065844

  • 1. Ototoxicity due to cis-diamminedichloroplatinum in the treatment of ovarian cancer: influence of dosage and schedule of administration.
    Waters GS, Ahmad M, Katsarkas A, Stanimir G, McKay J.
    Ear Hear; 1991 Apr; 12(2):91-102. PubMed ID: 2065844
    [Abstract] [Full Text] [Related]

  • 2. Ototoxicity of cis-diamminedichloroplatinum (II): influence of dose, schedule and mode of administration.
    Vermorken JB, Kapteijn TS, Hart AA, Pinedo HM.
    Eur J Cancer Clin Oncol; 1983 Jan; 19(1):53-8. PubMed ID: 6682776
    [Abstract] [Full Text] [Related]

  • 3. Ototoxic effects of supradose cisplatin with sodium thiosulfate neutralization in patients with head and neck cancer.
    Madasu R, Ruckenstein MJ, Leake F, Steere E, Robbins KT.
    Arch Otolaryngol Head Neck Surg; 1997 Sep; 123(9):978-81. PubMed ID: 9305250
    [Abstract] [Full Text] [Related]

  • 4. Relationship between cisplatin administration and the development of ototoxicity.
    Rademaker-Lakhai JM, Crul M, Zuur L, Baas P, Beijnen JH, Simis YJ, van Zandwijk N, Schellens JH.
    J Clin Oncol; 2006 Feb 20; 24(6):918-24. PubMed ID: 16484702
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Development and validation of a cisplatin dose-ototoxicity model.
    Dille MF, Wilmington D, McMillan GP, Helt W, Fausti SA, Konrad-Martin D.
    J Am Acad Audiol; 2012 Feb 20; 23(7):510-21. PubMed ID: 22992258
    [Abstract] [Full Text] [Related]

  • 9. Evoked otoacoustic emissions--an approach for monitoring cisplatin induced ototoxicity in children.
    Stavroulaki P, Apostolopoulos N, Segas J, Tsakanikos M, Adamopoulos G.
    Int J Pediatr Otorhinolaryngol; 2001 May 31; 59(1):47-57. PubMed ID: 11376818
    [Abstract] [Full Text] [Related]

  • 10. Ototoxicity of high-dose cisplatin by bolus administration in patients with advanced cancers and normal hearing.
    Kopelman J, Budnick AS, Sessions RB, Kramer MB, Wong GY.
    Laryngoscope; 1988 Aug 31; 98(8 Pt 1):858-64. PubMed ID: 3398663
    [Abstract] [Full Text] [Related]

  • 11. [Cisplatin ototoxicity: series of cases].
    Mota LA, Melo MS, Santos MH, de Albuquerque KM, Tavares Cde L.
    Rev Assoc Med Bras (1992); 2007 Aug 31; 53(4):370-3. PubMed ID: 17823744
    [Abstract] [Full Text] [Related]

  • 12. A review of cis-platinum ototoxicity.
    Moroso MJ, Blair RL.
    J Otolaryngol; 1983 Dec 31; 12(6):365-9. PubMed ID: 6686617
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss.
    Reavis KM, Phillips DS, Fausti SA, Gordon JS, Helt WJ, Wilmington D, Bratt GW, Konrad-Martin D.
    Ear Hear; 2008 Dec 31; 29(6):875-93. PubMed ID: 18753950
    [Abstract] [Full Text] [Related]

  • 15. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer.
    Bokemeyer C, Berger CC, Hartmann JT, Kollmannsberger C, Schmoll HJ, Kuczyk MA, Kanz L.
    Br J Cancer; 1998 Apr 31; 77(8):1355-62. PubMed ID: 9579846
    [Abstract] [Full Text] [Related]

  • 16. High-dose cisplatin treatment: hearing loss and plasma concentrations.
    Laurell G, Jungnelius U.
    Laryngoscope; 1990 Jul 31; 100(7):724-34. PubMed ID: 2362532
    [Abstract] [Full Text] [Related]

  • 17. The utility of acoustic reflex thresholds and other conventional audiologic tests for monitoring cisplatin ototoxicity in the pediatric population.
    Park KR.
    Ear Hear; 1996 Apr 31; 17(2):107-15. PubMed ID: 8698156
    [Abstract] [Full Text] [Related]

  • 18. Progressive hearing loss after completion of cisplatin chemotherapy is common and more pronounced in children without spontaneous otoacoustic emissions before chemotherapy.
    Weissenstein A, Deuster D, Knief A, Zehnhoff-Dinnesen AA, Schmidt CM.
    Int J Pediatr Otorhinolaryngol; 2012 Jan 31; 76(1):131-6. PubMed ID: 22104469
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.